Successful immunotherapy in a murine metastasizing fibrosarcoma model

Area of Science:

• Oncology
• Immunology
• Cancer Metastasis Research

Background:

• Primary murine fibrosarcoma exhibits antigenic differences compared to its metastases.
• Previous immunization strategies using only primary tumor cells failed to protect against metastatic challenge.

Purpose of the Study:

• To investigate the efficacy of immunotherapy targeting distinct antigens of primary and metastatic fibrosarcoma.
• To evaluate the impact of combining immunotherapy with surgery and chemotherapy on survival and metastasis.

Main Methods:

• Mice were immunized with irradiated primary tumor cells (TC) or pulmonary metastatic cells (PMC).
• Tumor-bearing mice underwent limb resection (Amp) combined with cyclophosphamide (Cy), TC, PMC, or combinations.
• Survival rates and pulmonary metastasis incidence were assessed.

Main Results:

• Immunization with TC protected against TC challenge but not PMC challenge, and vice versa.
• Amputation plus cyclophosphamide improved survival but did not prevent metastasis or achieve 100-day survival.
• Immunotherapy significantly improved survival and decreased pulmonary metastases; combinations of TC and PMC antigens were superior to single antigen preparations.
• Chemotherapy did not enhance immunotherapy and surgery outcomes.
• Long-term survivors developed permanent immunity.

Conclusions:

• Targeting diverse antigens present in both primary and metastatic fibrosarcoma is crucial for effective immunotherapy.
• Combined immunotherapy with surgery offers significant survival benefits and reduces metastasis in murine fibrosarcoma models.
• The study highlights the potential of multi-antigen immunotherapy for overcoming tumor heterogeneity and immune evasion.